---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-256654"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:56:30.243686+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Seres receives Nasdaq bid-price deficiency notice; Q3 net loss $51M from cont. ops; SER-155 shows 77% BSI reduction

## Summary
- Nasdaq notified Seres (MCRB) that bid price closed below $1.00 for 30 consecutive business days; must regain compliance by May 6, 2025.
- Q3 2024 net loss from continuing ops $51M (vs $41M in Q3 2023); R&D exp $16.5M, G&A $12.7M.
- SER-155 Phase 1b: 77% relative risk reduction in bloodstream infections, lower antibiotic use & febrile neutropenia vs placebo; Breakthrough Therapy requested.
- VOWST sale closed Sep 2024 for ~$175M gross proceeds; expects $50M in Jan 2025 and $25M in Jul 2025; no debt outstanding.
- Cash $66.8M as of Sep 30; expects to fund into Q4 2025 with existing cash and installment payments.

## SEC filing metadata
- accession: 0001193125-24-256654
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/0001193125-24-256654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312524256654/d912869d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-256654
- JSON: https://secwatch.observer/filing/0001193125-24-256654.json
- Plain text: https://secwatch.observer/filing/0001193125-24-256654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.